Effective treatment options for chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients with the T315I mutation are few. This study compared overall survival (OS) between CML and Ph+ ALL patients treated with ponatinib versus allogeneic stem cell transplantation (allo-SCT).
Name: Ponatinib (Iclusig®)
Description: Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.Type: DrugPonatinib (PACE trial)
Name: allogeneic stem cell transplantation
Type: ProcedureAllogenis stem cell transplantation (EBMT registry)
Cohort
There is one SNP
Overall Survival With Ponatinib Versus Allogeneic Stem Cell Transplant in Philadelphia-positive Leukemias With the T315I Mutation. --- T315I ---
Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I Effective treatment options for chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients with the T315I mutation are few. --- T315I ---
Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I Effective treatment options for chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients with the T315I mutation are few. --- T315I --- --- T315I ---
Inclusion Criteria: - CML any phase with T315I mutation - Ph+ ALL with a T315I mutation - Being treated in the PACE trial according to the criteria of this phase II trial - Or being allogeneic stem cell transplanted with any source of allogeneic cells and after any conditioning regimen. --- T315I ---
Inclusion Criteria: - CML any phase with T315I mutation - Ph+ ALL with a T315I mutation - Being treated in the PACE trial according to the criteria of this phase II trial - Or being allogeneic stem cell transplanted with any source of allogeneic cells and after any conditioning regimen. --- T315I --- --- T315I ---
Exclusion Criteria: - Ph negative patients - Patients under 18 years Inclusion Criteria: - CML any phase with T315I mutation - Ph+ ALL with a T315I mutation - Being treated in the PACE trial according to the criteria of this phase II trial - Or being allogeneic stem cell transplanted with any source of allogeneic cells and after any conditioning regimen. --- T315I ---
Exclusion Criteria: - Ph negative patients - Patients under 18 years Inclusion Criteria: - CML any phase with T315I mutation - Ph+ ALL with a T315I mutation - Being treated in the PACE trial according to the criteria of this phase II trial - Or being allogeneic stem cell transplanted with any source of allogeneic cells and after any conditioning regimen. --- T315I --- --- T315I ---